|
 The phase 3 trial will test LY-CoV555, a treatment developed in
partnership with Canadian biotech AbCellera, is expected to enroll
up to 2,400 participants who live or work at a facility that have
had a recently diagnosed case of COVID-19.
"COVID-19 has had a devastating impact on nursing home residents,"
Lilly's chief scientific officer Daniel Skovronsky said in a
statement. "We’re working as fast as we can to create medicines that
might stop the spread of the virus to these vulnerable individuals."
Lilly is already testing the drug in hospitals to study whether it
can work as a treatment in patients who have the disease. This trial
will test whether it works prophylactically.
It is launching the phase 3 trial in partnership with several
long-term care facility networks across the country as well as the
U.S. National Institute of Allergy and Infectious Diseases (NIAID).
Lilly said in order to speed the study it has created mobile
research units including retrofitted recreational vehicles that can
be deployed in response to outbreaks of the virus at nursing homes
across the U.S.
[to top of second column] |
LY-CoV555 belongs to a class of treatments known as monoclonal antibodies that
are among the most widely used biotechnology medicines. Regeneron
Pharmaceuticals Inc and other drugmakers are testing similar treatments against
COVID-19.
Last week Lilly told investors that LY-CoV555 had moved into mid-stage trials as
a treatment and would start late stage-trials in the coming weeks. It expects
efficacy data from the mid-stage trial in the fourth quarter.
(Reporting by Michael Erman; Editing by Christopher Cushing)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
